Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation

Ken Ichi Kozaki, Osamu Miyaishi, Tetsuya Tsukamoto, Yoshio Tatematsu, Toyoaki Hida, Toshitada Takahashi, Takashi Takahashi

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Lymphogenous metastasis is a common feature of human lung cancers, but very little is known about the underlying mechanism. In the present study, in vivo selection was carried out to obtain a highly lymphogenous metastatic subline of a human large cell carcinoma of the lung, NCI-H460. The resulting subline, termed NCI-H460-LNM35 (LNM35), was shown to metastasize to regional lymph nodes with a 100% incidence not only as a result of orthotopic intrabronchial (i.b.) implantation, but also as a result of conventional s.c. implantation. LNM35 has a short latency period, allowing for the collection of experimental data within 28 days after i.b. inoculation and 45 days after s.c. inoculation. It was noted that orthotopically i.b.-propagated LNM35 closely mimicked the clinical manifestations of human lung cancer patients by infiltrating into lymphatic vessels and metastasizing to the mediastinal lymph nodes. The LNM35 cell line is, to the best of our knowledge, the first human lung cancer cell line to be reported as having lymphogenous metastatic properties, and the observed 100% incidence by s.c. inoculation gives LNM35 a significant advantage even over previously reported human cancer cell lines of other origins. Comparisons between LNM35 and its parental NCI-H460 cell lines were also made with regard to expression levels and/or activities of various molecules that are thought to play a part in the metastatic process. We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.

Original languageEnglish
Pages (from-to)2535-2540
Number of pages6
JournalCancer Research
Volume60
Issue number9
Publication statusPublished - May 1 2000
Externally publishedYes

Fingerprint

Lung Neoplasms
Neoplasm Metastasis
Cell Line
nimesulide
Lymph Nodes
Large Cell Carcinoma
Lymphatic Vessels
Cyclooxygenase 2 Inhibitors
Incidence
Cyclooxygenase 2
Basement Membrane
Lung
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kozaki, K. I., Miyaishi, O., Tsukamoto, T., Tatematsu, Y., Hida, T., Takahashi, T., & Takahashi, T. (2000). Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Research, 60(9), 2535-2540.

Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. / Kozaki, Ken Ichi; Miyaishi, Osamu; Tsukamoto, Tetsuya; Tatematsu, Yoshio; Hida, Toyoaki; Takahashi, Toshitada; Takahashi, Takashi.

In: Cancer Research, Vol. 60, No. 9, 01.05.2000, p. 2535-2540.

Research output: Contribution to journalArticle

Kozaki, KI, Miyaishi, O, Tsukamoto, T, Tatematsu, Y, Hida, T, Takahashi, T & Takahashi, T 2000, 'Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation', Cancer Research, vol. 60, no. 9, pp. 2535-2540.
Kozaki, Ken Ichi ; Miyaishi, Osamu ; Tsukamoto, Tetsuya ; Tatematsu, Yoshio ; Hida, Toyoaki ; Takahashi, Toshitada ; Takahashi, Takashi. / Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. In: Cancer Research. 2000 ; Vol. 60, No. 9. pp. 2535-2540.
@article{fce3483b656b4c91a3105435fb841dd8,
title = "Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation",
abstract = "Lymphogenous metastasis is a common feature of human lung cancers, but very little is known about the underlying mechanism. In the present study, in vivo selection was carried out to obtain a highly lymphogenous metastatic subline of a human large cell carcinoma of the lung, NCI-H460. The resulting subline, termed NCI-H460-LNM35 (LNM35), was shown to metastasize to regional lymph nodes with a 100{\%} incidence not only as a result of orthotopic intrabronchial (i.b.) implantation, but also as a result of conventional s.c. implantation. LNM35 has a short latency period, allowing for the collection of experimental data within 28 days after i.b. inoculation and 45 days after s.c. inoculation. It was noted that orthotopically i.b.-propagated LNM35 closely mimicked the clinical manifestations of human lung cancer patients by infiltrating into lymphatic vessels and metastasizing to the mediastinal lymph nodes. The LNM35 cell line is, to the best of our knowledge, the first human lung cancer cell line to be reported as having lymphogenous metastatic properties, and the observed 100{\%} incidence by s.c. inoculation gives LNM35 a significant advantage even over previously reported human cancer cell lines of other origins. Comparisons between LNM35 and its parental NCI-H460 cell lines were also made with regard to expression levels and/or activities of various molecules that are thought to play a part in the metastatic process. We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.",
author = "Kozaki, {Ken Ichi} and Osamu Miyaishi and Tetsuya Tsukamoto and Yoshio Tatematsu and Toyoaki Hida and Toshitada Takahashi and Takashi Takahashi",
year = "2000",
month = "5",
day = "1",
language = "English",
volume = "60",
pages = "2535--2540",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Establishment and characterization of a human lung cancer cell line NCI- H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation

AU - Kozaki, Ken Ichi

AU - Miyaishi, Osamu

AU - Tsukamoto, Tetsuya

AU - Tatematsu, Yoshio

AU - Hida, Toyoaki

AU - Takahashi, Toshitada

AU - Takahashi, Takashi

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Lymphogenous metastasis is a common feature of human lung cancers, but very little is known about the underlying mechanism. In the present study, in vivo selection was carried out to obtain a highly lymphogenous metastatic subline of a human large cell carcinoma of the lung, NCI-H460. The resulting subline, termed NCI-H460-LNM35 (LNM35), was shown to metastasize to regional lymph nodes with a 100% incidence not only as a result of orthotopic intrabronchial (i.b.) implantation, but also as a result of conventional s.c. implantation. LNM35 has a short latency period, allowing for the collection of experimental data within 28 days after i.b. inoculation and 45 days after s.c. inoculation. It was noted that orthotopically i.b.-propagated LNM35 closely mimicked the clinical manifestations of human lung cancer patients by infiltrating into lymphatic vessels and metastasizing to the mediastinal lymph nodes. The LNM35 cell line is, to the best of our knowledge, the first human lung cancer cell line to be reported as having lymphogenous metastatic properties, and the observed 100% incidence by s.c. inoculation gives LNM35 a significant advantage even over previously reported human cancer cell lines of other origins. Comparisons between LNM35 and its parental NCI-H460 cell lines were also made with regard to expression levels and/or activities of various molecules that are thought to play a part in the metastatic process. We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.

AB - Lymphogenous metastasis is a common feature of human lung cancers, but very little is known about the underlying mechanism. In the present study, in vivo selection was carried out to obtain a highly lymphogenous metastatic subline of a human large cell carcinoma of the lung, NCI-H460. The resulting subline, termed NCI-H460-LNM35 (LNM35), was shown to metastasize to regional lymph nodes with a 100% incidence not only as a result of orthotopic intrabronchial (i.b.) implantation, but also as a result of conventional s.c. implantation. LNM35 has a short latency period, allowing for the collection of experimental data within 28 days after i.b. inoculation and 45 days after s.c. inoculation. It was noted that orthotopically i.b.-propagated LNM35 closely mimicked the clinical manifestations of human lung cancer patients by infiltrating into lymphatic vessels and metastasizing to the mediastinal lymph nodes. The LNM35 cell line is, to the best of our knowledge, the first human lung cancer cell line to be reported as having lymphogenous metastatic properties, and the observed 100% incidence by s.c. inoculation gives LNM35 a significant advantage even over previously reported human cancer cell lines of other origins. Comparisons between LNM35 and its parental NCI-H460 cell lines were also made with regard to expression levels and/or activities of various molecules that are thought to play a part in the metastatic process. We show here that the expression of cyclooxygenase 2 is increased in LNM35 and that a specific cyclooxygenase 2 inhibitor, nimesulide, can inhibit the invasion of LNM35 in vitro through Matrigel containing basement membrane components.

UR - http://www.scopus.com/inward/record.url?scp=0034192370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034192370&partnerID=8YFLogxK

M3 - Article

C2 - 10811136

AN - SCOPUS:0034192370

VL - 60

SP - 2535

EP - 2540

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -